-
CStone Pharmaceuticals' registrational clinical study for the first-line treatment of esophageal squamous cell carcinoma has reached the primary endpoint and intends to submit a marketing application for ® a new indication
Time of Update: 2023-02-03
On January 3, 2023, CStone Pharmaceuticals (02616. HK) reported that its potentially best-in-class PD-L1 antibody Zogeminec (sugemelimab ® injection) first-line clinical study for esophageal squamous
-
Improving innovation capabilities has become a general trend in the industry, and pharmaceutical equipment companies will continue to increase investment in research and development in the future
Time of Update: 2023-02-03
In the future, pharmaceutical equipment companies will continue to increase investment in research and development (Image source: Pharmaceutical Network) It is reported that in China, the head pharmaceutical machine companies represented by Chutian Technology and Dongfulong have been continuously increasing investment in research and development, constantly enriching product categories, optimizing product structure, actively deploying new tracks such as biopharmaceuticals and vaccines, and continuously meeting the downstream localization replacement needs while promoting the high-quality development of the industry.
-
In 2023, the price of Yanhusuo is expected to fall, and Longshen Rongfa's profit will grow!
Time of Update: 2023-02-03
According to the company's 2022 half-year report data, Yuanhu painkiller pills occupy a high share in Yuanhu painkiller series products due to their exclusive dosage form and unique curative effect, and currently account for 70% of the company's operating income.
-
How to use Chinese medicine decoction well for urban and rural grassroots epidemic prevention and control? How to effectively choose Chinese medicine formulas after infection? ——Authoritative experts interpret hot issues in epidemic prevention
Time of Update: 2023-02-03
The use of medicinal decoctions in urban and rural areas to carry out the treatment of new coronavirus infection is an important measure for us to adopt the "Chinese method" to solve China's anti-epidemic problem.
-
Bei Shen Pharmaceutical: a listed enterprise on the New Third Board, focusing on the inheritance and innovation of traditional Chinese medicine, and being an expert in respiratory medicine
Time of Update: 2023-02-03
With the brand concept of "focusing on the inheritance and innovation of traditional Chinese medicine, and carrying forward the characteristics of traditional Chinese medicine", Bei Shen Pharmaceutical has experienced 22 years of development, and now has 14 drug approval numbers, 7 dosage form production lines, and an annual total production value of 500 million.
-
Domestic pharmaceutical companies stormed the 100 billion anti-tumor drug market, and there is good news!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Recently, CT Tianqing Pharmaceutical's self-developed Class 1 new drug TQB2102 for injection has obtained the implied license of clinical trials and is intended to be used for the treatment of advanced malignant tumors.
-
The State Food and Drug Administration approved the import registration of Monoravir capsules, Merck's new coronavirus treatment drug
Time of Update: 2023-02-03
(Zhongxin Finance) According to the official website of the State Food and Drug Administration, on December 29, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration conducted emergency review and approval in accordance with the special approval procedures for drugs, and conditionally approved the import registration of Merck's new coronavirus treatment drug monogravir capsules (trade name: Lizhuorui/LAGEVRIO).
-
In 2022, the sales of ibuprofen are expected to exceed 1.4 billion yuan, and China Resources Sanjiu and Renfu will enter the market to grab food
Time of Update: 2023-02-03
According to data, since the beginning of this year, 14 new anti-inflammatory and anti-rheumatic drugs (by product + enterprise statistics) have been approved for marketing.
According to data, since the beginning of this year, 14 new anti-inflammatory and anti-rheumatic drugs (by product + enterprise statistics) have been approved for marketing.
-
Accelerate the layout of diabetes, and strive for the research and development of new anti-aging drugs... At the beginning of the new year of 2023, pharmaceutical companies are busy with financing
Time of Update: 2023-02-03
Sihuan Pharmaceutical recently announced that Huisheng Biotechnology, a non-wholly-owned subsidiary of the Group, has successfully completed the Series A+ financing conducted by Jilin Baixing Bai Rong Investment Center (Limited Partnership), Jilin Equity Fund Investment Co.
-
Many places in China have issued implementation plans for the new crown infection "Class B tube"
Time of Update: 2023-02-03
Recently, many provinces in China have successively introduced specific implementation plans for the "Class B and B tube" of new crown infection, increased investment in the construction of medical resources, increased fever clinics, clarified the reimbursement policy of medical insurance for new crown infection, and ensured the needs of the people for medical treatment.
-
This week, a number of pharmaceutical companies announced important personnel changes!
Time of Update: 2023-02-03
BMS announces intercontinental leadership team changes On January 4, Bristol-Myers Squibb officially announced changes to the Intercontinental leadership team to employees, and effective January 1, 2023, Chen Siyuan was promoted to Vice President and General Manager of China and Asia Regional Markets.
-
In 2023, the pharmaceutical industry policy eased and stabilized, and it is recommended to focus on these three areas
Time of Update: 2023-02-03
Innovative drugs: In recent years, the development of the innovative drug industry has continued, the supply of high-quality has continued to increase, and the company's domestic business + overseas business has continuously achieved breakthroughs.
-
Over $3.3 billion in 4 days! Eli Lilly, Merck and other pharmaceutical companies have joined hands with him to develop peptide-conjugated drugs
Time of Update: 2023-02-03
It is understood that recently, PeptiDream announced that it has entered into cooperation and licensing agreements with Merck and Eli Lilly respectively to discover and develop novel peptide conjugates (PDCs) targeting multiple drug targets, with a total amount of more than $3.
-
2023 Chinese medicine industry two major plays: the new version of the basic drug catalogue and the centralized procurement of traditional Chinese medicine
Time of Update: 2023-02-03
In addition to the national centralized procurement of traditional Chinese medicines, the release of a new version of the basic drug catalogue in 2023 is also the focus of attention in the industry.
-
Comparable to the world's most expensive drug of $3.5 million, Pfizer hemophilia B gene therapy Phase 3 clinical data is positive
Time of Update: 2023-02-03
Recently, Pfizer announced that its gene therapy for severe hemophilia type B Fidanacogene Elaparvovec has achieved excellent results in a Phase 3 clinical trial, reaching the primary clinical endpoint, and the number of annual bleeding times in patients receiving gene therapy was 1.
-
The net outflow of funds of 5 pharmaceutical and biological stocks exceeded 100 million yuan, involving Yiling Pharmaceutical and Zhongsheng Pharmaceutical
Time of Update: 2023-02-03
According to the statistics of capital flow data, among the stocks with a net outflow of funds from the pharmaceutical and biological industry on December 29, there were 5 stocks with a net outflow o
-
The first batch of listed pharmaceutical companies released the annual report performance forecast, and the net profit of these companies is expected to increase by more than 100%
Time of Update: 2023-02-03
According to the data, Shanwaishan is mainly engaged in the research and development, production and sales of blood purification equipment and consumables, and provides chain hemodialysis medical services.
-
National medical insurance negotiations officially launched, a number of tumors, rare disease new drugs and other blockbuster products participated in the "soul bargaining"
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)]; The National Health Insurance Administration previously announced the "List of Declared Drugs Approved for Formal Review for the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022", with a total of 343 drugs officially passing the formal review.
-
In 2023, there will be active mergers and acquisitions in the pharmaceutical circle, involving Aier Ophthalmology, China Resources Pharmaceutical, Dajia Wellcom, etc
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];M&A is a common action of pharmaceutical companies, and due to the impact of the epidemic in 2022, the market has cooled down, and the overall M&A activity of the pharmaceutical industry has declined.
-
The State Food and Drug Administration approved the application for supplementation of production and capacity expansion of 5 symptomatic treatment drugs for new coronavirus infection, including ibuprofen tablets
Time of Update: 2023-02-03
Annex: List of varieties serial number Name of the drug Marketing Authorization Holder 1 Ibuprofen tablets Shandong Xinhua Pharmaceutical Co.
Annex: List of varieties serial number Name of the drug Marketing Authorization Holder 1 Ibuprofen tablets Shandong Xinhua Pharmaceutical Co.
